Literature DB >> 11882914

Relaxant effect of capsazepine in the isolated rat ileum.

Emilia Nocerino1, Angelo A Izzo, Francesca Borrelli, Francesco Capasso, Raffaele Capasso, Aldo Pinto, Lidia Sautebin, Nicola Mascolo.   

Abstract

We have evaluated the effect of the vanilloid receptor agonists resiniferatoxin (RTX), capsaicin and piperine and of the vanilloid receptor antagonist capsazepine on the resting tone in the isolated rat ileum. Capsazepine (10(-8)-3 x 10(-5) M) produced a concentration-related relaxation (8 +/-3%-49 +/-3%) of the rat ileum. By contrast RTX (up to 10(-8) M), capsaicin (up to 10(-6) M) and piperine (up to 10(-5) M) were without effect. Pre-treatment with capsaicin [either in vivo (50 mg/kg s.c.) or in vitro (10(-6) M)] did not modify the inhibitory effect of capsazepine. The L-type Ca2+ channel antagonist nifedipine (10(-6) M), but not the N-type Ca2+ channel antagonist omega-conotoxin GVIA (3 x 10(-8) M) nor the Na+ channel blocker tetrodotoxin (3 x 10(-7) M), counteracted the inhibitory effect of capsazepine. The NK1 receptor antagonist SR 140333 (10(-7) M), the NK2 receptor antagonist SR 48968 (10(-6) M), the NK3 receptor antagonist SR 142801 (10(-7) M), atropine (10(-6) M), hexamethonium (10(-4) M), phentolamine (10(-6) M) plus propranolol (10(-6) M), N(G)-nitro- L-arginine methyl ester ( L-NAME 3 x 10(-4) M), apamin (10(-7) M), methysergide (10(-6) M), the calcitonin gene-related peptide (CGRP) antagonist hCGRP 8-37 (1.5 x 10(-6) M), the VIP antagonist hGRF 1-29 (10(-5) M) did not modify the inhibitory effect of capsazepine. Capsazepine (2.5-40 mg/kg) also decreased upper gastrointestinal transit in vivo. It is concluded that the vanilloid antagonist capsazepine has a direct relaxing effect on rat intestinal smooth muscle which could involve L-type calcium channels. We found no evidence to suggest that capsazepine is antagonizing an endogenous vanilloid.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11882914     DOI: 10.1007/s00210-001-0522-x

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  7 in total

1.  Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice.

Authors:  Angelo A Izzo; Raffaele Capasso; Gabriella Aviello; Francesca Borrelli; Barbara Romano; Fabiana Piscitelli; Laura Gallo; Francesco Capasso; Pierangelo Orlando; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

2.  Inhibitory effect of the herbal antidepressant St. John's wort (Hypericum perforatum) on rat gastric motility.

Authors:  Raffaele Capasso; Francesca Borrelli; Gabriella Aviello; Francesco Capasso; Angelo A Izzo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-03       Impact factor: 3.000

Review 3.  Small molecule vanilloid TRPV1 receptor antagonists approaching drug status: can they live up to the expectations?

Authors:  Arpad Szallasi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-06-14       Impact factor: 3.000

4.  Pharmacological characterization of cannabinoid receptor activity in the rat-isolated ileum myenteric plexus-longitudinal muscle preparation.

Authors:  R Makwana; A Molleman; M E Parsons
Journal:  Br J Pharmacol       Date:  2010-03-05       Impact factor: 8.739

5.  Effects of piperine, the pungent component of black pepper, at the human vanilloid receptor (TRPV1).

Authors:  Fergal N McNamara; Andrew Randall; Martin J Gunthorpe
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

6.  Vanilloid receptor (TRPV1)-deficient mice show increased susceptibility to dinitrobenzene sulfonic acid induced colitis.

Authors:  F Massa; A Sibaev; G Marsicano; H Blaudzun; M Storr; B Lutz
Journal:  J Mol Med (Berl)       Date:  2005-12-31       Impact factor: 4.599

7.  ThermoTRP channels in nociceptors: taking a lead from capsaicin receptor TRPV1.

Authors:  Sravan Mandadi; Basil D Roufogalis
Journal:  Curr Neuropharmacol       Date:  2008-03       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.